How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

13,936 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity (PubMed)

Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity We show that suppression of the spliceosome has potential for the treatment of cutaneous squamous cell carcinoma (cSCC). The small-molecule inhibitors of the spliceosome at the most advanced stage of development target the splicing factor SF3B1/SF3b155. The majority of cSCC cell lines are more sensitive than normal skin cells to death (...) for a key role of the p53 pathway in the response to spliceosome disruption. SF3B1 inhibition causes wild-type p53 upregulation associated with altered mRNA splicing and reduced protein expression of both principal p53 negative regulators MDMX/MDM4 and MDM2. We observed that wild-type p53 can promote pladienolide B-induced death in tumour cells. However, p53 is commonly inactivated by mutation in cSCCs and p53 participates in killing normal skin cells at high concentrations of pladienolide B. This may

Full Text available with Trip Pro

2018 Oncotarget

162. Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib (PubMed)

, Dallas, Texas. eng Case Reports 2018 04 30 United States JAAD Case Rep 101665210 2352-5126 BCC, basal cell carcinoma JAK, Janus kinase Janus kinase SCC, squamous cell carcinoma myelofibrosis polycythemia vera ruxolitinib skin cancer 2018 7 10 6 0 2018 7 10 6 0 2018 7 10 6 1 epublish 29984281 10.1016/j.jdcr.2018.01.001 S2352-5126(18)30007-9 PMC6031591 Leukemia. 2016 Aug;30(8):1701-7 27211272 J Drugs Dermatol. 2017 May 1;16(5):508-511 28628689 N Engl J Med. 2015 Jan 29;372(5):426-35 25629741 Drugs (...) Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib 29984281 2019 02 26 2352-5126 4 5 2018 Jun JAAD case reports JAAD Case Rep Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib. 455-457 10.1016/j.jdcr.2018.01.001 Aboul-Fettouh Nader N Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas. Nijhawan Rajiv I RI Department of Dermatology, University of Texas Southwestern Medical Center

Full Text available with Trip Pro

2018 JAAD Case Reports

163. WNT ligands control initiation and progression of human papillomavirus-driven squamous cell carcinoma (PubMed)

WNT ligands control initiation and progression of human papillomavirus-driven squamous cell carcinoma Human papillomavirus (HPV)-driven cutaneous squamous cell carcinoma (cSCC) is the most common cancer in immunosuppressed patients. Despite indications suggesting that HPV promotes genomic instability during cSCC development, the molecular pathways underpinning HPV-driven cSCC development remain unknown. We compared the transcriptome of HPV-driven mouse cSCC with normal skin and observed higher (...) amounts of transcripts for Porcupine and WNT ligands in cSCC, suggesting a role for WNT signaling in cSCC progression. We confirmed increased Porcupine expression in human cSCC samples. Blocking the secretion of WNT ligands by the Porcupine inhibitor LGK974 significantly diminished initiation and progression of HPV-driven cSCC. Administration of LGK974 to mice with established cSCC resulted in differentiation of cancer cells and significant reduction of the cancer stem cell compartment. Thus, WNT/β

Full Text available with Trip Pro

2018 Oncogene

164. Rapid onset of multiple concurrent squamous cell carcinomas associated with the use of an arsenic-containing traditional medicine for chronic plaque psoriasis (PubMed)

Rapid onset of multiple concurrent squamous cell carcinomas associated with the use of an arsenic-containing traditional medicine for chronic plaque psoriasis We report a case of a 46-year-old Vietnamese man who developed widespread, numerous and concurrent cutaneous squamous cell carcinomas (SCCs) in non-sun exposed skin areas after taking a traditional medicine (TM) formulation for chronic plaque psoriasis. The SCC lesions began to develop within 12-15 months after beginning the arsenic

Full Text available with Trip Pro

2018 BMJ case reports

165. A Case Report of Scrotal Squamous Cell Carcinoma Secondary to Chronic Urinary Irritation (PubMed)

A Case Report of Scrotal Squamous Cell Carcinoma Secondary to Chronic Urinary Irritation Most scrotum cancers are associated with occupational exposure. We report a case of a squamous cell carcinoma of the scrotum in a patient with a proximal meatus, secondary to mistreated urethral stricture. Based on our observations in this case, we think that chronic urinary inflammation of the scrotal skin may also be considered as a risk factor of scrotal cancer.

Full Text available with Trip Pro

2018 Cureus

166. A Review of the Literature of Surgical and Nonsurgical Treatments of Invasive Squamous Cells Carcinoma (PubMed)

A Review of the Literature of Surgical and Nonsurgical Treatments of Invasive Squamous Cells Carcinoma Cutaneous squamous cell carcinoma (cSCC) is an increasing public health problem. It is a primary malignant skin tumor with Malpighian differentiation and together with basal cell carcinoma is classified among nonmelanoma skin cancers (NMSCs). cSCC usually occurs on photoexposed areas, such as the head, the neck, and the extremities, and its incidence increases with age. Invasive forms (...) of this skin tumor tend to be more aggressive showing a higher metastatic potential, usually regarding regional lymph nodes. Treatment options for invasive cSCCs include both surgical and nonsurgical options. The therapeutic choice depends on several factors, such as anatomic location, risk factors for tumor recurrence, age, and health status of the patient. This review aims to provide an overview of the current evidence on therapeutic surgical and nonsurgical management of invasive cSCC.

Full Text available with Trip Pro

2018 BioMed research international

167. Squamous cell carcinoma arising in a chronic perineal wound in a patient with long-standing cutaneous Crohn's disease (PubMed)

hidradenitis suppurativa inflammatory bowel disease medical dermatology skin manifestations of internal diseases squamous cell carcinoma 2018 4 26 6 0 2018 4 26 6 0 2018 4 26 6 1 epublish 29693066 10.1016/j.jdcr.2017.11.007 S2352-5126(17)30282-5 PMC5911976 Am J Gastroenterol. 1991 Dec;86(12):1829-32 1962632 Surg Oncol. 2013 Dec;22(4):230-7 24050823 Cutis. 2013 Jul;92(1):35-9 23961524 J Crohns Colitis. 2013 Jul;7(6):e232-5 23069004 J Am Col Certif Wound Spec. 2011 Sep;3(3):60-4 24525526 J Crohns Colitis (...) Squamous cell carcinoma arising in a chronic perineal wound in a patient with long-standing cutaneous Crohn's disease 29693066 2019 02 26 2352-5126 4 4 2018 May JAAD case reports JAAD Case Rep Squamous cell carcinoma arising in a chronic perineal wound in a patient with long-standing cutaneous Crohn's disease. 346-348 10.1016/j.jdcr.2017.11.007 Powell Helen B HB University of North Carolina School of Medicine, Chapel Hill, North Carolina. Googe Paul B PB Department of Dermatology, University

Full Text available with Trip Pro

2018 JAAD Case Reports

168. Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab (PubMed)

Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab Cutaneous squamous cell carcinomas (SCC) affecting the regions of the head and neck can be challenging to resect surgically and refractory to chemotherapy or radiation therapy. Consequently; the treatment of squamous cell carcinomas of the skin is a focus of current research. One such advancement is immunotherapy. Herein we describe clinical remission of invasive, poorly differentiated squamous (...) cell carcinoma of the pre-auricular region with external auditory canal involvement using cetuximab, an epidermal growth factor receptor (EGFR) antibody; and nivolumab, a programmed death receptor-1 (PD-1) antibody. Such durable and comprehensive disease resolution demonstrates the therapeutic potential of cetuximab and nivolumab in surgically challenging, treatment-resistant cutaneous squamous cell carcinoma.

Full Text available with Trip Pro

2018 Journal of clinical medicine

169. Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B (PubMed)

Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B Notch 1/2 genes play tumor-suppressing functions in squamous cell carcinoma (SCC), a very common malignancy in skin and internal organs. In contrast with Notch, we show that the transcription factor CSL (also known as RBP-Jκ), a key effector of canonical Notch signaling endowed with intrinsic transcription-repressive functions, plays a tumor-promoting function in SCC development. Expression of this gene (...) decreased in upper epidermal layers and human keratinocytes (HKCs) undergoing differentiation, while it increased in premalignant and malignant SCC lesions from skin, head/neck, and lung. Increased CSL levels enhanced the proliferative potential of HKCs and SCC cells, while silencing of CSL induced growth arrest and apoptosis. In vivo, SCC cells with increased CSL levels gave rise to rapidly expanding tumors, while cells with silenced CSL formed smaller and more differentiated tumors with enhanced

Full Text available with Trip Pro

2018 The Journal of clinical investigation

170. Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition (PubMed)

Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition Cutaneous squamous cell carcinoma (cSCC) is the second most common type of non-melanoma skin cancer. Platinum-based regimens have been an integral part of palliative care for patients with locally advanced or metastatic disease. There is no evidence of efficacy for later lines of chemotherapy and no targeted therapy has been introduced as 'standard of care'. Here we report on the case (...) of an elderly cSCC patient, resistant to conventional therapy, however successfully treated with anti-epidermal growth factor receptor (EGFR) agent (Cetuximab) in addition to a daily dose of Curcumin phospholipid. The patient responded to treatment and experienced no recurrence for 11 months with only minor skin-related toxicity. To our knowledge, this is the first report of clinical evidence that an anti EGFR targeted therapy with a daily oral dose of Curcumin phospholipid is well tolerated and results

Full Text available with Trip Pro

2018 Molecular and clinical oncology

171. Squamous Cell Carcinomas in Two Cases of Nail Lichen Planus: Is There a Real Association? (PubMed)

Squamous Cell Carcinomas in Two Cases of Nail Lichen Planus: Is There a Real Association? Lichen planus (LP) is a chronic inflammatory disease that affects the skin and oral mucosa. Although its etiology is unknown, its potential for cancerization has been confirmed. We herein report the cases of a brother and sister, both with a 15-year history of nail lichen planus of the fingers and toes, who developed squamous cell carcinomas of the nail bed and matrix. This article shows the potential

Full Text available with Trip Pro

2018 Dermatology and therapy

172. Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomas (PubMed)

Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomas Cutaneous squamous cell carcinoma (SCC) is among the most common cancers in humans, and many patients with SCC will develop multiple tumors within their lifetime. The field cancerization concept, originally proposed over 60 years ago, hypothesized that multiple primary cancers may arise simultaneously and coexist with subclinical precursor lesions within a defined field. Genetic sequencing (...) of SCC and precursor lesions has identified what may be the earliest clonal proliferations in SCC development and confirmed that field cancerization in the skin is mediated by ultraviolet radiation. For patients with multiple SCCs and severe actinic damage, treatment of precursor lesions within a cancerized field can decrease the risk of subsequent cancer development. Sunblock is an effective intervention for field cancerization, even in patients with established disease. There is now direct evidence

Full Text available with Trip Pro

2018 F1000Research

173. WW domain-containing E3 ubiquitin protein ligase 1 depletion evokes antitumor effect in cutaneous squamous cell carcinoma by inhibiting signal transducer and activator of transcription 3 signaling pathway (PubMed)

WW domain-containing E3 ubiquitin protein ligase 1 depletion evokes antitumor effect in cutaneous squamous cell carcinoma by inhibiting signal transducer and activator of transcription 3 signaling pathway Objectives WW domain-containing E3 ubiquitin protein ligase 1 (WWP1) has been implicated in tumor progression. We aimed to investigate the role of WWP1 in cutaneous squamous cell carcinoma (CSCC). Methods WWP1 gene and protein levels were detected using semi-quantitative reverse transcription (...) -polymerase chain reaction, immunohistochemistry and western blotting. The effects of WWP1 on cell cycle, apoptosis, cell migration and invasion were examined by flow cytometry, wound healing and Transwell assays, respectively. The antitumor efficacy of WWP1 small interfering RNA was determined in CSCC tumor xenografts in mice. Results WWP1 expression was significantly higher in CSCC tissues and cells than in normal skin and cells, respectively. WWP1 expression was significantly associated

Full Text available with Trip Pro

2018 The Journal of international medical research

174. A giant cutaneous squamous cell carcinoma of the neck (PubMed)

101517926 IM Aged Carcinoma, Squamous Cell diagnosis pathology Fatal Outcome Head and Neck Neoplasms diagnosis pathology Humans Male Skin Neoplasms diagnosis pathology Squamous Cell Carcinoma of Head and Neck Skin chemotherapy squamous cell carcinoma 2018 01 26 2018 05 01 2018 9 1 6 0 2018 9 1 6 0 2018 10 3 6 0 epublish 30167050 10.11604/pamj.2018.30.22.14984 PAMJ-30-22 PMC6110546 (...) A giant cutaneous squamous cell carcinoma of the neck 30167050 2018 10 01 2019 02 21 1937-8688 30 2018 The Pan African medical journal Pan Afr Med J A giant cutaneous squamous cell carcinoma of the neck. 22 10.11604/pamj.2018.30.22.14984 Bazine Aziz A Medical Oncology Department, Military Hospital Moulay Ismaïl, Meknès, Morocco. Fetohi Mohamed M Medical Oncology Department, Military Hospital Moulay Ismaïl, Meknès, Morocco. eng Case Reports Journal Article 2018 05 15 Uganda Pan Afr Med J

Full Text available with Trip Pro

2018 The Pan African medical journal

175. Advanced squamous-cell carcinoma of the lower lip (PubMed)

Beneficência, Ribeirão Preto, São Paulo, Brazil. eng Case Reports Journal Article 2018 06 20 Uganda Pan Afr Med J 101517926 IM Adult Carcinoma, Squamous Cell diagnosis pathology therapy Fatal Outcome Humans Lip Neoplasms diagnosis pathology therapy Male Prognosis Squamous Cell carcinoma neglected diseases skin neoplasms 2017 11 09 2018 05 19 2018 10 31 6 0 2018 10 31 6 0 2018 12 13 6 0 epublish 30374394 10.11604/pamj.2018.30.148.14352 PAMJ-30-148 PMC6201625 (...) Advanced squamous-cell carcinoma of the lower lip 30374394 2018 12 12 2018 12 12 1937-8688 30 2018 The Pan African medical journal Pan Afr Med J Advanced squamous-cell carcinoma of the lower lip. 148 10.11604/pamj.2018.30.148.14352 Filho Fred Bernardes FB Dermatology Division, Department of Medical Clinics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil. Grupioni Priscila Vinhal PV Department of Oncology, Hospital Imaculada Conceição da Sociedade Portuguesa de

Full Text available with Trip Pro

2018 The Pan African medical journal

176. Squamous Cell Carcinoma Arising within Verruca Vulgaris on the Nipple (PubMed)

Squamous Cell Carcinoma Arising within Verruca Vulgaris on the Nipple Cutaneous squamous cell carcinoma (SCC) is a common form of skin cancer and often appears as a hard, scaly lump that occasionally ulcerates. It is usually associated with cumulative exposure to ultraviolet light, although prior scarring, chronic wounds, exposure to radiation, HPV infection, and immunosuppression are also associated risk factors. Primary SCC of the nipple is very rare and only a few cases have been reported

Full Text available with Trip Pro

2018 Case reports in dermatological medicine

177. The volatilome – investigation of volatile organic metabolites (VOM) as potential tumor markers in patients with head and neck squamous cell carcinoma (HNSCC) (PubMed)

factors, nutritional and disease status. As a result of pathological processes the individual body odor can be influenced by newly produced or altered compositions of the VOM. Until now, human VOM have been detected in various body media, such as on the skin, in the exhaled air as well as in body fluids such as saliva, mother's milk, sweat, blood and urine.In this retrospective case-control study urinary VOM of 53 therapy-naive patients with head and neck squamous cell carcinoma (HNSCC) and 82 healthy (...) The volatilome – investigation of volatile organic metabolites (VOM) as potential tumor markers in patients with head and neck squamous cell carcinoma (HNSCC) Different organisms such as bacteria, molds and humans produce and release a relative unknown class of metabolites which are responsible for the individual olfactory pattern. These volatile organic metabolites (VOM) represent a kind of biosignature that reflects the sum of all multifactorial influences, including genetics, environmental

Full Text available with Trip Pro

2018 Journal of Otolaryngology - Head & Neck Surgery

178. Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

their doses prior to dye administration Mean QT interval corrected for heart rate (QTc) greater than or equal to 470 ms calculated from 3 electrocardiograms (EKGs) using Fridericia's Correction Any concurrent malignancies; exceptions include- basal cell carcinoma of the skin, squamous cell carcinoma of the skin of a secondary location, superficial bladder cancer or in situ cervical cancer that has undergone potentially curative therapy. Patients with a history of other prior malignancy must have been (...) Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2018 Clinical Trials

179. Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"

disease at presentation. History of prior invasive malignancy diagnosed within 2 years prior to study enrollment; exceptions are malignancies with a low risk of metastasis or death (e.g., expected 5-year overall survival (OS) > 90%) that were treated with an expected curative outcome, such as squamous cell carcinoma of the skin, in-situ carcinoma of the cervix uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer (TNM stage of T1a (...) Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)" Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)" - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies

2018 Clinical Trials

180. Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.

Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial. Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial. (CITHARE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>